Mexico and Moderna Ink 5-Year Strategic Deal to Localize mRNA Vaccine Production

Mexico has entered into a long-term strategic partnership with Moderna to secure a stable supply of mRNA vaccines for respiratory diseases over the next five years. The agreement includes a significant technology transfer component, allowing the Mexican pharmaceutical firm Liomont to produce COVID-19 vaccines locally. This initiative is a cornerstone of the 'Plan Mexico' economic framework, which seeks to drive industrial growth and enhance domestic manufacturing capabilities. By localizing production, Mexico aims to strengthen its national health security while providing Moderna with a reliable revenue stream in the Latin American market. The deal highlights Moderna's strategy to expand its international footprint amidst evolving regulatory landscapes in the United States. Market observers view this partnership as a positive step for both Mexico's industrial sector and Moderna's long-term growth prospects.